Patrick A. Kupelian
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Patrick A. Kupelian has a total of 63 co-authors. Here are the top co-authors by number of shared publications:
- Chandana A. Reddy
Department of Radiation Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH
5 shared publications Alan Forbes
2 shared publicationsDeepak Khuntia
Department of Radiation Oncology, Cleveland Clinic Foundation, Cleveland, Ohio, USA
2 shared publicationsEric A Klein
2 shared publicationsEric A. Klein
Department of Urology, Cleveland Clinic Foundation, Cleveland, Ohio
2 shared publications- Eric A. Klein
GRAIL, Inc, Menlo Park, CA
2 shared publications
Latest Publications
- 1 January 2011
- Vol. 163, 567-73
Visualization of 3D volumetric lung dynamics for real-time external beam lung radiotherapy.
This paper reports on the usage of physics-based 3D volumetric lung dynamic models for visualizing and monitoring the radiation dose deposited on the lung of a human subject during lung radiotherapy. The dynamic model of each subject is computed from a 4D Computed Tomography (4DCT) imaging acquired before the treatment. The 3D lung deformation and the radiation dose deposited are computed using Graphics Processing Units (GPU). Additionally, using the dynamic lung model, the airflow inside the lungs during the treatment is also investigated. Results show the radiation dose deposited on the lung tumor as well as the surrounding tissues, the combination of which is patient-specific and varies from one treatment fraction to another.
- 1 January 2011
- Vol. 163, 567-73
Visualization of 3D volumetric lung dynamics for real-time external beam lung radiotherapy.
This paper reports on the usage of physics-based 3D volumetric lung dynamic models for visualizing and monitoring the radiation dose deposited on the lung of a human subject during lung radiotherapy. The dynamic model of each subject is computed from a 4D Computed Tomography (4DCT) imaging acquired before the treatment. The 3D lung deformation and the radiation dose deposited are computed using Graphics Processing Units (GPU). Additionally, using the dynamic lung model, the airflow inside the lungs during the treatment is also investigated. Results show the radiation dose deposited on the lung tumor as well as the surrounding tissues, the combination of which is patient-specific and varies from one treatment fraction to another.
- 15 March 2008
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 70 (4) , 1272-1280
Investigation of Accelerated Partial Breast Patient Alignment and Treatment With Helical Tomotherapy Unit
- 15 March 2008
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 70 (4) , 1272-1280
Investigation of Accelerated Partial Breast Patient Alignment and Treatment With Helical Tomotherapy Unit
- 1 February 2005
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 61 (2) , 415-419
Improved biochemical relapse-free survival with increased external radiation doses in patients with localized prostate cancer: The combined experience of nine institutions in patients treated in 1994 and 1995
- 1 February 2005
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 61 (2) , 415-419
Improved biochemical relapse-free survival with increased external radiation doses in patients with localized prostate cancer: The combined experience of nine institutions in patients treated in 1994 and 1995
- Open Access
Recurrence‐free survival rates after external‐beam radiotherapy for patients with clinical T1–T3 prostate carcinoma in the prostate‐specific antigen era
BACKGROUND: The objective of the current study was to report biochemical recurrence–free survival (bRFS) rates among men with T1–T3 prostate carcinoma who were treated with external‐beam radiotherapy (RT) at the Cleveland Clinic Foundation (Cleveland, OH).METHODS: In total, 1352 patients were identified between 1987 and 2000 with a minimum follow‐up of 1 year (median follow‐up, 55 months; range, 12–189 months). The median radiation dose was 74.0 grays (Gy) (range, 63.0–83.0 Gy). The median radiation doses for patients who received < 68.0 Gy (n = 201), 68.0–72.0 Gy (n = 373), and ≥ 72.0 Gy (n = 778) were 66.6 Gy, 70.0 Gy, and 78.0 Gy, respectively. The RT techniques used were standard RT in 41% of patients, 3‐dimensional conformal RT in 34% of patients, and intensity‐modulated RT in 25% of patients. Androgen‐deprivation (AD) therapy lasting ≤ 6 months was administered to 34% of patients.RESULTS: The 5‐year and 7‐year bRFS rates were 63% and 59%, respectively. On multivariate analysis, T classification (P < 0.001), pretreatment prostate‐specific antigen level (P < 0.001), biopsy Gleason score (P = 0.001), radiation dose (P < 0.001), and year of therapy (P < 0.001) were independent predictors of biochemical failure. Age, race, AD therapy, and RT technique did not predict for biochemical failure. For patients with low‐risk tumors, the 5‐year bRFS rates for those who received RT doses of ≤ 68.0 Gy, 68.0–72.0 Gy, and ≥ 72.0 Gy were 52%, 82%, and 93%, respectively (P < 0.001); for patients with intermediate‐risk tumors, the respective 5‐year bRFS rates were 27%, 51%, and 83% (P < 0.001); and for patients with high‐risk tumors, the respective 5‐year bRFS rates were 21%, 29%, and 71%, respectively (P < 0.001).CONCLUSIONS: The most significant therapeutic factor affecting bRFS rates after RT was radiation dose, rather than AD therapy use or radiation technique. Cancer 2004. © 2004 American Cancer Society.
Open AccessRecurrence‐free survival rates after external‐beam radiotherapy for patients with clinical T1–T3 prostate carcinoma in the prostate‐specific antigen era
BACKGROUND: The objective of the current study was to report biochemical recurrence–free survival (bRFS) rates among men with T1–T3 prostate carcinoma who were treated with external‐beam radiotherapy (RT) at the Cleveland Clinic Foundation (Cleveland, OH).METHODS: In total, 1352 patients were identified between 1987 and 2000 with a minimum follow‐up of 1 year (median follow‐up, 55 months; range, 12–189 months). The median radiation dose was 74.0 grays (Gy) (range, 63.0–83.0 Gy). The median radiation doses for patients who received < 68.0 Gy (n = 201), 68.0–72.0 Gy (n = 373), and ≥ 72.0 Gy (n = 778) were 66.6 Gy, 70.0 Gy, and 78.0 Gy, respectively. The RT techniques used were standard RT in 41% of patients, 3‐dimensional conformal RT in 34% of patients, and intensity‐modulated RT in 25% of patients. Androgen‐deprivation (AD) therapy lasting ≤ 6 months was administered to 34% of patients.RESULTS: The 5‐year and 7‐year bRFS rates were 63% and 59%, respectively. On multivariate analysis, T classification (P < 0.001), pretreatment prostate‐specific antigen level (P < 0.001), biopsy Gleason score (P = 0.001), radiation dose (P < 0.001), and year of therapy (P < 0.001) were independent predictors of biochemical failure. Age, race, AD therapy, and RT technique did not predict for biochemical failure. For patients with low‐risk tumors, the 5‐year bRFS rates for those who received RT doses of ≤ 68.0 Gy, 68.0–72.0 Gy, and ≥ 72.0 Gy were 52%, 82%, and 93%, respectively (P < 0.001); for patients with intermediate‐risk tumors, the respective 5‐year bRFS rates were 27%, 51%, and 83% (P < 0.001); and for patients with high‐risk tumors, the respective 5‐year bRFS rates were 21%, 29%, and 71%, respectively (P < 0.001).CONCLUSIONS: The most significant therapeutic factor affecting bRFS rates after RT was radiation dose, rather than AD therapy use or radiation technique. Cancer 2004. © 2004 American Cancer Society.
- Top Cited Papers
- 1 January 2004
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 58 (1) , 25-33
Radical prostatectomy, external beam radiotherapy <72 Gy, external beam radiotherapy ≥72 Gy, permanent seed implantation, or combined seeds/external beam radiotherapy for stage T1–T2 prostate cancer
- 1 January 2004
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 58 (1) , 25-33
Top Cited PapersRadical prostatectomy, external beam radiotherapy <72 Gy, external beam radiotherapy ≥72 Gy, permanent seed implantation, or combined seeds/external beam radiotherapy for stage T1–T2 prostate cancer
- 1 November 2003
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 57 (3) , 629-634
Improvement in relapse-free survival throughout the PSA era in patients with localized prostate cancer treated with definitive radiotherapy: Year of treatment an independent predictor of outcome
- 1 November 2003
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 57 (3) , 629-634
Improvement in relapse-free survival throughout the PSA era in patients with localized prostate cancer treated with definitive radiotherapy: Year of treatment an independent predictor of outcome
- 1 September 2003
- Published by Springer Nature in World Journal of Urology
- Vol. 21 (4) , 190-199
External beam radiation therapy: role of androgen deprivation
- 1 September 2003
- Published by Springer Nature in World Journal of Urology
- Vol. 21 (4) , 190-199
External beam radiation therapy: role of androgen deprivation